From Depot to Delivered: Expanding Access Through our Supply Chain

From Depot to Delivered: Expanding Access Through our Supply Chain

When a doctor requests treatment for a patient in an out-of-reach country, my job is to ensure medicine gets to that patient. Multiply this by 30,000 patients across 70+ countries, and our supply chain becomes a complex system of forecasting demand, requesting donations, shipping medicines, tracking product and confirming deliveries at each destination.

I recently spoke at the ReConnect 2021 conference, along with my colleague Michael Wrigglesworth, Senior Director of Program Strategy and Data Solutions, about how The Max Foundation connects supply chain and technology. It was an opportunity to share how our unique patient-centric model is supported by our supply chain activities that increase global access to treatment.

 

The two-day event featured speakers from diverse organizations, including other NGOs, such as VillageReach discussing drone delivery of medicines, and industry, such as logistics provider Expeditors International. Our presentation was entitled “Medicine Distribution in Low- and Middle-Income Countries: Technologies and Supply Chains” and was moderated by Dr. Surya Pathak, professor at the University of Washington School of Business.

The well-organized conference enabled us to provide some practical examples of how our Patient Access Tracking System is enhancing processes to make our supply chain more data-driven. Through interconnected technology, we’re able to successfully track stocks of medicine and forecast for future deliveries, all to get medicine into the hands of those in need. Particularly over the past 18 months of the global pandemic, we have remained resolute in our commitment to maximize our impact through innovation and collaboration.

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • The GIPAP Program Detailed in the ASCO Journal of Global Oncology

    The GIPAP Program Detailed in the ASCO Journal of Global Oncology

    Last week ASCO launched the inaugural issue of the Journal of Global Oncology. This new open access, online journal focuses exclusively on cancer research, treatment, and the delivery of care in middle and low resource countries.

    Among the first seven articles, published on September 23rd, are original research, commentaries, and review articles, including a special article looking at the Glivec International Patient Assistance Program (GIPAP), authored by our CEO Pat Garcia-Gonzalez, MS, and others.

  • A life of challenge giving way to hope for the future

    A life of challenge giving way to hope for the future

    Setu Kumari Khadka was born in Nepal in 1989 to much celebration, as the first daughter born into her family after several generations.  Setu remembers being weak and having health issues as a child and having to be taken to Mumbai, India for diagnosis and hospitalized there. No cause for her weakness came out of….

  • The “Last Mile” to Treatment Access: Constantine’s Story

    The “Last Mile” to Treatment Access: Constantine’s Story

    For many people facing cancer, the “last mile” in treatment access is a long, expensive, and recurring journey. But in Constantine’s case, even this journey may not be enough. The distance itself is not so far but the journey is long – 8 hours by public buses and transport. Constantine, like so many others around the world, has a rare form of leukemia called CML (chronic myeloid leukemia).